Wound care, diagnostics not in German cost savings law
This article was originally published in Clinica
Wound care products, prescription medical devices and diagnostics are outside the scope of the newly-announced German law on costs savings for medication products. The drug products cost-effectiveness law (AVWG) aims to reduce expenditure on medications by some E1.3bn ($1.5bn) per year via a series of measures. These were announced on February 17 and will go into effect on April 1.
You may also be interested in...
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.